Table 1 Baseline Characteristics of Patients Based on Atrial Fibrillation
From: Short- and long-term outcomes of patients with minor stroke and nonvalvular atrial fibrillation
Variables | Total | NVAF | Non-AF | P value |
|---|---|---|---|---|
(n = 4753 [100%]) | (n = 222 [4.7%]) | (n = 4531 [95.3%]) | ||
Age, y | 61.9 ± 11.1 | 71.1 ± 8.9 | 61.4 ± 11.0 | < 0.001 |
Female | 1413 (29.7) | 69 (31.1) | 1344 (29.7) | 0.65 |
Medical history | Â | Â | Â | Â |
 Current smoking | 1563 (32.9) | 43 (19.4) | 1520 (33.5) | < 0.001 |
 Hypertension | 3005 (63.2) | 138 (62.2) | 2867 (63.3) | 0.74 |
 Diabetes mellitus | 1114 (23.4) | 41 (18.5) | 1073 (23.7) | 0.07 |
 Dyslipidemia | 381 (8.0) | 19 (8.6) | 362 (8.0) | 0.76 |
 Prior CAD | 509 (10.7) | 65 (29.3) | 444 (9.8) | < 0.001 |
 Heart failure | 23 (0.5) | 8 (3.6) | 15 (0.3) | < 0.001 |
 Prior Stroke/TIA | 1073 (22.6) | 49 (22.1) | 1024 (22.6) | 0.85 |
 PVD | 40 (0.8) | 2 (0.9) | 38 (0.8) | 0.92 |
 BMI | 24.7 (22.9–26.7) | 24.2 (22.0-26.4) | 24.7 (22.9–26.7) | 0.06 |
Baseline NIHSS | 2.0 (1.0–4.0) | 2.0 (1.0–4.0) | 2.0 (1.0–4.0) | 0.37 |
 0 | 591 (12.4) | 28 (12.6) | 563 (12.4) |  |
 1 | 965 (20.3) | 35 (15.8) | 930 (20.5) |  |
 2 | 1038 (21.8) | 58 (26.1) | 980 (21.6) |  |
 3 | 851 (17.9) | 31 (14.0) | 820 (18.1) |  |
 4 | 774 (16.3) | 44 (19.8) | 730 (16.1) |  |
 5 | 534 (11.2) | 26 (11.7) | 508 (11.2) |  |
CHA2DS2-VASc | 2.0 (1.0–3.0) | 3.0 (2.0–4.0) | 2.0 (1.0–3.0) | < 0.001 |
Time measure | Â | Â | Â | Â |
 Onset to door, hours | 5.9 (2.4–12.4) | 3.7 (1.6–7.2) | 6.0 (2.5–12.6) | < 0.001 |
  ≤3 h | 1513 (31.8) | 97 (43.7) | 1416 (31.3) |  |
  3-4.5 h | 503 (10.6) | 33 (14.9) | 470 (10.4) |  |
  >4.5 h | 2737 (57.6) | 92 (41.4) | 2645 (58.4) |  |
 Length of stay | 12.0 (10.0–15.0) | 13.0 (10.0–15.0) | 12.0 (10.0–14.0) | 0.10 |
Laboratory | Â | Â | Â | Â |
 Baseline blood glucose, mmol/L | 5.5 (4.9-7.0) | 5.5 (4.9–6.5) | 5.5 (4.9-7.0) | 0.21 |
 Serum creatinine, µmol/L | 69.0 (58.0–81.0) | 75.8 (63.3–92.0) | 69.0 (58.0–80.0) | < 0.001 |
 Serum ALT, U/L | 18.0 (13.0–25.0) | 17.0 (13.0–25.0) | 18.0 (13.0–25.0) | 0.24 |
SBP at admission, mmHg | 150.0 (136.5–165.0) | 147.0 (134.0-164.0) | 150.0 (137.0-165.0) | 0.001 |
DBP at admission, mmHg | 87.0 (80.0–96.0) | 83.5 (77.0–91.0) | 87.0 (80.0-96.5) | < 0.001 |
Medication history | Â | Â | Â | Â |
 Antiplatelet | 823 (17.3) | 76 (34.2) | 747 (16.5) | < 0.001 |
 Anticoagulant | 29 (0.6) | 15 (6.8) | 14 (0.3) | < 0.001 |
In-hospital treatment | Â | Â | Â | Â |
 Thrombolysis | 647 (13.6) | 38 (17.1) | 609 (13.4) | 0.12 |
 EVT | 8 (0.2) | 1 (0.5) | 7 (0.2) | 0.29 |
 Antiplatelet | 4640 (97.6) | 192 (86.5) | 4448 (98.2) | < 0.001 |
 Anticoagulant | 402 (8.5) | 104 (46.8) | 298 (6.6) | < 0.001 |
  Warfarin | 74 (1.6) | 60 (27.0) | 14 (0.3) | < 0.001 |
  DOACs |  |  |  |  |
   Rivaroxaban | 4 (0.1) | 2 (0.9) | 2 (0.0) | < 0.001 |
   Dabigatran | 16 (0.3) | 14 (6.3) | 2 (0.0) | < 0.001 |
 Antihypertensive agents | 2251 (47.4) | 106 (47.7) | 2145 (47.3) | 0.91 |
 Lipid-lowering agents | 4577 (96.3) | 213 (95.9) | 4364 (96.3) | 0.78 |
 Glucose-lowering agents | 1202 (25.3) | 38 (17.1) | 1164 (25.7) | 0.004 |